Medicyte GmbH Signs Agreement with Life Technologies to Develop Next Generation Upcyte® CellsLife Technologies

News

Medicyte GmbH Signs Agreement with Life Technologies to Develop Next Generation Upcyte® Cells
27 Mar 2013

Medicyte has signed a licensing agreement for the rights to use Lentiviral vector technology from Life Technologies to develop and market next generation, cell-based upcyte® cell products to the biopharma and academic research markets.

Various data, already presented at academic meetings, indicates that Medicyte’s upcyte® hepatocytes combine the benefits of quantity (generation of up to 2000 vials per donor) with the quality of primary hepatocytes. The new generation of upcyte® hepatocytes show more comparable results to primary cells in in-vitro assays (such as CYP 3A4-Induction, genotoxicity or hepato- and cytotoxicity). ‘With the technology we have licensed from Life Technologies, we are capable to bring more predictive, reliable, and standardized cell strains on the market’ commented Dr. Joris Braspenning, CEO of Medicyte GmbH

Request Info

Company website